|
|
|
15.06.26 - 16:54
|
A Dramatic Shift in Fed Policy Just Unlocked a New Era for Bristol Myers Squibb (24/7 Wall St.)
|
|
|
With the 10-Year Treasury yielding 4.48% and the Fed signaling more cuts ahead, income investors are hunting for yield that compounds. Bristol Myers Squibb (NYSE:BMY) offers a 4.39% yield backed by 94 consecutive years of dividend payments. The pharma giant is rebuilding around a Growth Portfolio (Eliquis, Camzyos, Breyanzi) while legacy drugs face generic erosion. ... A Dramatic Shift in Fed Policy Just Unlocked a New Era for Bristol Myers Squibb...
|
|
|
|
|
|
|
|
|
|
|
|
|
10.06.26 - 08:39
|
Nxera Joins OpenFold AI Research Consortium Alongside Leading Global Pharmaceutical and AI Companies to Accelerate AI-enabled Drug Discovery (GlobeNewswire EN)
|
|
|
Tokyo, Japan and Cambridge, UK, 10 June 2026 – Nxera Pharma Co., Ltd. (“Nxera” or the “Company”) announces that it has joined OpenFold, a non-profit AI research consortium that promotes the development of open-source AI software tools for biology and drug discovery. Technology companies, including Amazon Web Services, Microsoft and NVIDIA, participate in OpenFold as supporting members and the consortium has expanded into an international ecosystem comprising numerous pharmaceutical companies, biotechnology companies, technology companies and academic institutions, including Bristol Myers Squibb, Novo Nordisk, Bayer and Roche....
|
|
|
09.06.26 - 15:03
|
Blue Matter Expands Capabilities in Healthcare Policy Support for Life Sciences Led by Partner, Milena Sullivan (Business Wire)
|
|
|
NEW YORK--(BUSINESS WIRE)--Blue Matter today announced the launch of an expanded policy capability to support biopharma clients, led by Milena Sullivan, a Partner who joined the firm in December 2025.
Milena Sullivan brings more than 20 years of experience in healthcare policy, advocacy, and market access, advising life science companies, trade associations, and provider organizations on policy issues shaping their business. Prior to joining Blue Matter, she spent almost a decade with Avalere Health, where most recently she led the policy practice. She has also held in-house policy roles at Bristol-Myers Squibb and Novartis Vaccines and Diagnostics, as well as policy positions in the nonprofit space, including at the Center for Strategic and International Studies (CSIS). She holds an MA in International Policy and Practice from The George Washington University and a BA from Miami University of Ohio.
At Blue Matter, Milena is leading a policy capability that integrates directly into the firm's broad range...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
02.06.26 - 11:15
|
Bristol-Myers Squibb: Wird dieser Pharmakonzern massiv unterschätzt? (Sharedeals)
|
|
|
Die Aktie von Bristol-Myers Squibb steht seit Jahren unter dem Eindruck auslaufender Blockbuster-Medikamente und drohender Patentverluste. Doch die jüngsten Geschäftszahlen zeigen ein Unternehmen, dessen Wachstumstreiber inzwischen die Führung übernommen haben – eine Entwicklung, die sich nach Ansicht vieler Anleger bislang nicht ausreichend im Aktienkurs widerspiegelt. Neue Wachstumsbasis übernimmt die Führung Über Jahre dominierte an der […]
The post Bristol-Myers Squibb: Wird dieser Pharmakonzern massiv unterschätzt? first appeared on sharedeals.de....
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
